We report a 35 year old male, human immunodeficiency virus (HIV)-infected patient with acquired immune deficiency syndrome (AIDS), who presented with rapidly progressive pulmonary Kaposi's sarcoma. The tumour regressed with treatment with liposomal daunorubicin and remained in partial remission until the patient died 12 months later from complications of HIV infection. Liposomal daunorubicin may be a safe and effective alternative to the treatment protocols in current use for pulmonary Kaposi's sarcoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/09031936.94.07040824 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Pulmonary Kaposi sarcoma after lung transplantation: a case report and literature review].
Zhonghua Jie He He Hu Xi Za Zhi
January 2025
Department of Organ Transplantation, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou510120, China.
To investigate the clinical features, diagnosis, and treatment of pulmonary Kaposi sarcoma (KS) after lung transplantation. A case of pulmonary KS after bilateral lung transplantation was retrospectively analyzed. Two key words "Kaposi sarcoma" and "lung transplant*" were used to search for relevant literature in SinoMed, Wanfang Data, CNKI, PubMed, Embase, Cochrane Library and Web of Science, with a cut-off date of July 31, 2024.
View Article and Find Full Text PDFDisseminated Kaposi Sarcoma in a Patient With Hematemesis: A Case Report.
Cureus
October 2024
Department of Internal Medicine, Medical University of South Carolina, Charleston, USA.
Kaposi sarcoma (KS) is a soft tissue tumor primarily occurring in immunosuppressed patients and, although it has been described, dissemination of KS is rare. This case involves a patient with acquired immunodeficiency syndrome (AIDS) and biopsy-proven cutaneous KS presenting with hematemesis suspected due to gastrointestinal involvement in whom endoscopy with biopsy was contraindicated due to dual antiplatelet therapy (DAPT) and the hypervascular nature of KS tumors. Alternatively, the diagnosis was made via macroscopic findings on bronchoscopy, which demonstrated neovascular lesions, confirming visceral KS.
View Article and Find Full Text PDFSerologic screening and molecular surveillance of Kaposi sarcoma herpesvirus/human herpesvirus-8 infections for early recognition and effective treatment of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome in solid organ transplant recipients.
Am J Transplant
November 2024
Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Modena, Modena, Italy.
Article Synopsis
- Kaposi sarcoma herpesvirus/human herpesvirus-8 (HHV-8) poses serious health risks for solid organ transplant recipients, with higher seroprevalence noted in recipients (8.4%) compared to donors (3.3%).
- Among transplant patients, a specific group of donors (D+) and recipients (R-) showed notable rates of HHV-8-related diseases, like Kaposi sarcoma (KS) and associated inflammatory cytokine syndrome (KICS), emphasizing the importance of careful monitoring.
- Effective management of HHV-8 diseases, such as KICS, suggests that treatment options like rituximab can significantly impact patient outcomes, highlighting the need for serologic screening and timely interventions.
Development of KSHV vaccine platforms and chimeric MHV68-K-K8.1 glycoprotein for evaluating the immunogenicity and efficacy of KSHV vaccine candidates.
mBio
December 2024
Department of Cancer Biology and Infection Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Article Synopsis
- Kaposi's sarcoma-associated herpesvirus (KSHV) is responsible for diseases like Kaposi's Sarcoma and has a high prevalence in sub-Saharan Africa, making vaccine development critical, but existing challenges include the absence of viable animal models for KSHV infection.
- The study created a chimeric mouse virus (MHV68-K-K8.1) to mimic KSHV infection and tested two K8.1 vaccines (mRNA-LNP and Ferritin nanoparticles) which successfully stimulated immune responses in mice.
- Results showed that mice vaccinated with K8.1 mRNA LNP vaccines had reduced viral levels and reactivation rates of the surrogate virus, indicating the potential effectiveness of these
Prevalence of HIV in people with potential HIV-indicator conditions in Germany: an analysis of data from statutory health insurances.
EClinicalMedicine
July 2024
Institute for Healthcare Management and Research, University of Duisburg-Essen, Thea-Leymann-Str. 9, Essen, Germany.
Article Synopsis
- The study focuses on improving early diagnosis of HIV among individuals with specific conditions known as indicator conditions (ICs), which are associated with higher rates of undiagnosed HIV infections.
- Using data from over 513,000 German healthcare records from 2016 to 2021, the researchers analyzed the HIV prevalence among people with 26 selected ICs, finding notable rates especially in conditions like pneumocystosis and Kaposi's sarcoma.
- The findings indicated significant gender and age disparities, revealing that while many ICs showed high HIV prevalence in younger and middle-aged adults, some female patients had lower prevalence rates in certain conditions compared to males.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!